Jeff Frelick - 08 Jan 2026 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Reporting relationship: Chief Executive Officer
Issuer ticker: BBLG
Reported as of: 08 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:37:13 UTC
Prior SEC filing: 21 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeff Frelick

Key filing fact

Jeff Frelick filed Form 4 for Bone Biologics Corp (BBLG) on 21 Jan 2026.

Key facts

This page summarizes Jeff Frelick's Form 4 filing for Bone Biologics Corp (BBLG).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 21 Jan 2026, 16:37.

Change

Previous filing in this sequence was filed on 21 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001645093 Primary reporting owner

Frelick Jeff

Relationship: Chief Executive Officer
Address: C/O BONE BIOLOGICS CORP,, 2 BURLINGTON WOODS DR.SUITE 100, BURLINGTON,
Signature: /s/ Jeff Frelick
Signature date: 20 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBLG holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 360
Date: 08 Jan 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBLG transaction Derivative

Employee Stock Option

Award

Transaction value: $0
Shares: +16,668
Change %
Price: $0.000000
Shares after: 16,668
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,668
Exercise price: $1.55
Footnotes: F1

BBLG holding Derivative

Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,019
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,019
Exercise price: $5.82
Footnotes: F2

BBLG holding Derivative

Employee Stock Option

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8
Exercise price: $73800.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

Footnote F2

This option is fully vested as of the date of this report.